Correlation Between Bristol Myers and FibroGen

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Bristol Myers and FibroGen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and FibroGen into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Bristol Myers Squibb and FibroGen, you can compare the effects of market volatilities on Bristol Myers and FibroGen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of FibroGen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and FibroGen.

Diversification Opportunities for Bristol Myers and FibroGen

-0.35
  Correlation Coefficient

Very good diversification

The 3 months correlation between Bristol and FibroGen is -0.35. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and FibroGen in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on FibroGen and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with FibroGen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of FibroGen has no effect on the direction of Bristol Myers i.e., Bristol Myers and FibroGen go up and down completely randomly.

Pair Corralation between Bristol Myers and FibroGen

Assuming the 90 days trading horizon Bristol Myers Squibb is expected to generate 0.23 times more return on investment than FibroGen. However, Bristol Myers Squibb is 4.38 times less risky than FibroGen. It trades about 0.01 of its potential returns per unit of risk. FibroGen is currently generating about -0.04 per unit of risk. If you would invest  126,436  in Bristol Myers Squibb on September 1, 2024 and sell it today you would lose (4,236) from holding Bristol Myers Squibb or give up 3.35% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Bristol Myers Squibb  vs.  FibroGen

 Performance 
       Timeline  
Bristol Myers Squibb 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Bristol Myers showed solid returns over the last few months and may actually be approaching a breakup point.
FibroGen 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in FibroGen are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, FibroGen may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Bristol Myers and FibroGen Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Bristol Myers and FibroGen

The main advantage of trading using opposite Bristol Myers and FibroGen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, FibroGen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroGen will offset losses from the drop in FibroGen's long position.
The idea behind Bristol Myers Squibb and FibroGen pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Other Complementary Tools

Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Equity Valuation
Check real value of public entities based on technical and fundamental data
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges